Press Release FeedGet the RSS feed
Menu

Business Wire

Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026

Business Wire

  • Poster will characterize the efficacy of PIKTOR as a monotherapy and in combination with fulvestrant, oral SERDs, and CDK inhibitors in preclinical models of breast cancer

  • Poster also includes results from head-to-head comparisons with gedatolisib, another multi-nodal inhibitor of the PI3K-AKT-mTOR (PAM) pathway, in preclinical breast cancer xenograft models

  • The poster will be presented on Friday, October 23 at 15:15 CEST (9:15 a.m. ET). These preclinical data are intended to inform ongoing clinical development in the FTH-PIK-101 trial

AUSTIN, Texas, October 19, 2026--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will present preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

The poster will be presented on Friday, October 23, and will showcase preclinical data intended to inform the ongoing development of PIKTOR in the FTH-PIK-101 Phase 1b/2 trial in HR+/HER2- breast cancer. In the poster, PIKTOR is tested as monotherapy and in combination with fulvestrant, oral SERDs and CDK inhibitors, which are standard and emerging treatments for patients with HR+ breast cancer. Data from mouse xenograft models will be accompanied by cellular assays showing that in these preclinical models, PIKTOR suppressed key signaling nodes in the PAM pathway, including AKT, at rates comparable to or exceeding those observed with tested single-node inhibitors. The poster also compares PIKTOR head-to-head with gedatolisib in two preclinical breast cancer xenograft models.

A copy of the poster will be made available in the Investors section of Faeth's website at the start of the poster session.

Presentation Details:

Title: Characterising the efficacy of multi-node PI3K/AKT/mTOR pathway inhibition with serabelisib and sapanisertib (PIKTOR) in combination with SERDs and CDK inhibitors in models of HR+/HER2- breast cancer
Abstract Number: 431P
Session: Basic Science Poster Session
Date: Friday, October 23, 2026
Location: Poster Area - Hall 5
Time: 15:15 - 16:00 CEST (9:15 - 10:00 a.m. ET)
Presenter: Oliver Maddocks, Ph.D., Co-Founder & Chief Scientific Officer of Faeth Therapeutics

About PIKTOR

PIKTOR is an investigational, proprietary, all-oral combination of serabelisib, a selective PI3K-alpha inhibitor, and sapanisertib, an mTORC1/mTORC2 inhibitor, designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway. This multi-node approach is designed to address the signaling feedback reactivation and treatment-emergent resistance mutations that may limit the efficacy of single-node PI3K/AKT/mTOR pathway inhibitors. According to published literature, the PAM pathway is dysregulated in up to 50% of all solid tumors, making it one of the most prevalent therapeutic targets in oncology.

  1. HealthcarePharmaEssentia USA CorporationPharmaEssentia to Present Data at 18th International Congress on Myeloproliferative Neoplasms Highlighting Unmet Need with Current Therapies and Real-World Use of BESREMi® in Essential Thrombocythemia and Polycythemia VeraBESREMi (ropeginterferon alfa-2b njft), the first new FDA-approved treatment for essential thrombocythemia in nearly three decades, offers patients an alternative option beyond hydroxyurea and anagrelide More than half of patients with polycythemia vera remained on first-line BESREMi at two years in real-world practice BU
  2. Real estateDwight Capital and Dwight Investment Management Close $624MM in September 2026MIAMI, October 19, 2026--Dwight Capital and its affiliate, Dwight Investment Management , closed $624 million in real estate financings in September. Among the month's notable transactions was a $71.25 million bridge loan for a four-property, 646-bed skilled nursing portfolio across Montana and Colora
  3. Mötley Crüe to Play The Colosseum at Caesars Palace March 19-April 3, 2027Companies: Caesars EntertainmentMÖTLEY CRÜE AT THE COLOSSEUM AT CAESARS PALACE, CARNIVAL OF SINS IN SIN CITY LIMITED RUN OF SHOWS AT THE COLOSSEUM AT CAESARS PALACE MARCH 19 – APRIL 3, 2027 TICKETS GO ON SALE FRIDAY, OCT. 23 AT 10 A.M. PT A PORTION OF TICKET PROCEEDS WILL BENEFIT NEVADA PARTNERSHIP FOR HOMELESS YOUTH MÖTLEY CRÜE CELEBRATES 45 YEARS WITH THE TOO FAST FOR LOVE DEFINITIVE DELUXE LIMITED EDITION PRE-SAVE / PRE-ADD / PRE-ORDER HERE LAS
  4. FinanceMadison Square Garden Sports Corp.Yelophant Named Official Partner of the New York KnicksPartnership Highlighted by First-of-its-Kind Community Activation, "Fuel the Future Week" in China this Fall NEW YORK, October 19, 2026--Madison Square Garden Sports Corp. (NYSE: MSGS) announced today a new partnership with Yelophant, naming the modern food brand specializing in ready-to-heat Asian bre
  5. CybersecurityBluefinBluefin's TrustConex™ Wins 2026 CyberSecurity Breakthrough Award for Transaction Security Solution of the YearSecond consecutive CyberSecurity Breakthrough Award recognizes Bluefin's continued innovation in payment security, simplifying the deployment of PCI-validated encryption across complex payment environments. ATLANTA, October 19, 2026--Bluefin, a global leader in payment and data security, today announce
  6. FinanceTegriaTegria Acquires CloudWave, Strengthening Cybersecurity and Cloud Hosting CapabilitiesSPOKANE, Wash., October 19, 2026--Tegria , a global healthcare services and solutions company, today announced the acquisition of CloudWave , a full-service cybersecurity, cloud hosting, and managed IT services provider built exclusively for the healthcare industry. The strategic combination enhances